Drug Panel 7, Urine - Screen with Reflex to Confirmation/Quantitation
Also known as: CDASU 7
Use
This test is useful for general drug screening to assess compliance and potential drug abuse. It employs an initial screening method with a reflex to more definitive confirmation and quantitation tests. The test serves to rule out drug exposure and does not differentiate between the delta-8 and delta-9 forms of THC or their respective metabolites.
Special Instructions
If the initial screen indicates a positive result, reflex confirmation and quantitation testing are automatically performed using advanced methodologies, with additional charges applicable. This test is approved by the New York Department of Health for clinical use.
Limitations
The test might not detect all drugs or drug metabolites within a class, and presumptive negative results may arise from non-compliance, improper timing of specimen collection, poor drug absorption, diluted or adulterated urine, or inherent testing limitations. It is important to note that testing is for medical purposes only and is not valid for forensic applications.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 2161-8
- 77202-0
- 19261-7
- 19359-9
- 19300-3
- 19659-2
- 19292-2
- 19270-8
- 14316-4
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
8 mL
Minimum Volume
4 mL
Container
ARUP Standard Transport Tubes
Patient Preparation
Random urine.
Causes for Rejection
Specimens exposed to repeated freeze/thaw cycles.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 1 month |
| Frozen | 1 month |